Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Cambrex Corporation announced it will expand pilot plant capabilities at its High Point, NC facility with the installation of a fourth reactor suite.
read more
Thursday, October 07, 2021
Cambrex announced that it is expanding its manufacturing center of excellence in High Point, NC. The $30+ million investment is designed to meet the continually growing demand for small molecule development and manufacturing services.
read more
Thursday, November 14, 2019
Cambrex has won the ‘Excellence in Pharma: API Development’ category at the annual CPhI Pharma Awards, which took place at a Gala Dinner at CPhI Worldwide in Frankfurt on November 5th.
read more
Wednesday, January 17, 2018
Cambrex held an opening ceremony with AstraZeneca at its Sweden site to mark the commencement of a long-term manufacturing agreement between the two companies for a key intermediate.
read more
Tuesday, September 17, 2013
Global pharmaceutical chemistry leader Cambridge Major Laboratories, Inc. (CML) is pleased to announce the appointment of Dr. Mark Sawicki as Chief Business Officer. With executive leadership responsibility for the global sales and marketing ...
read more
Monday, November 04, 2013
Cambridge Major Laboratories, Inc. (“CML”), a global leader in pharmaceutical API development and manufacturing, and AAIPharma Services, Corp. (“AAIPharma”), a leading global provider of pharmaceutical analytical testing, product development and ...
read more
Tuesday, October 22, 2013
Global pharmaceutical chemistry leader Cambridge Major Laboratories Europe, B.V. (CML-Europe) is pleased to announce the successful completion of its first Food and Drug Administration inspection. The inspection included a pre-approval inspection and...
read more
Tuesday, October 07, 2014
Leading research peptide manufacturer [2]Cambridge Research Biochemicals (CRB) announced today that it has signed a non-exclusive license with The Scripps Research Institute (TSRI) to add click chemistry services, namely the “click” labelling of ...
read more
Wednesday, January 23, 2019
CAMP4 announced a research collaboration with Alnylam focused on identifying new druggable targets to address an undisclosed rare disease of the liver with a significant unmet need.
read more
Can-Fite BioPharma has signed a License, Collaboration and Distribution Agreement with CMS Medical for Piclidenoson for rheumatoid arthritis and psoriasis and Namodenoson for advanced liver cancer.
read more
The Canadain Government has signed a new contract with GlaxoSmithKline to support sustained influenza pandemic readiness.
read more
Thursday, August 08, 2024
The Government of Canada , represented by Charles Sousa, Parliamentary Secretary to the Minister of Public Services and Procurement, on behalf of the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, announced a ...
read more
CANbridge and WuXi Biologics jointly announced a strategic partnership to enable CANbridge to develop and commercialize a portfolio of biotherapeutics for the treatment of rare diseases.
read more
Boehringer Ingelheim and CANbridge Life Sciences announced that both parties have signed an agreement for the manufacture of CAN-017, an ErbB3 (HER3) inhibitory antibody to treat esophageal squamous cell cancer (ESCC), CANbridge plans to initiate a ...
read more
Cancer Prevention Pharmaceuticals announced the signing of a license agreement with Mallinckrodt wherein Mallinckrodt obtained exclusive North American commercialization rights to CPP-1X/sul.
read more